Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 33Other hematologic neoplasm 7Lymphoid 7Breast 6Thoracic 5Plasma cell 5Other neoplasm 3Dermatologic 3Gynecologic 2Genitourinary 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Hematologic Neoplasms 1

Interventions

fludarabine phosphate 140Cyclophosphamide 132Busulfan 102Peripheral Blood Stem Cell Transplantation 95Imatinib Mesylate 94Mycophenolic Acid 91Cytarabine 82Azacitidine 80Tacrolimus 79Cyclosporine 78Whole-Body Irradiation 77fludarabine 74Antilymphocyte Serum 71Methotrexate 65Filgrastim 63nilotinib 59Melphalan 51Decitabine 50Radiotherapy 43Dasatinib 34Granulocyte Colony-Stimulating Factor 33ruxolitinib 31Clofarabine 31Etoposide 30thymoglobulin 29Thiotepa 29Cord Blood Stem Cell Transplantation 28sargramostim 27Methylprednisolone 26Stem Cell Transplantation 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Darbepoetin alfa × Myeloid × Clear all
NCT00230321 2013-02-04

A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)

Stanford University

Phase 1/2 Completed
21 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡